Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study - Archive ouverte HAL Access content directly
Journal Articles Lancet Oncology Year : 2020

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

(1, 2) , , (3) , (4) , , , (5) , , , , (6) , , , , , , , (7) , , , , , (8)
1
2
3
4
5
6
7
8
Fichier principal
Vignette du fichier
S1470204520304496.pdf (532.39 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03493378 , version 1 (07-11-2022)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, Cora N Sternberg, Johann de Bono, et al.. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncology, 2020, 21, pp.1513 - 1525. ⟨10.1016/S1470-2045(20)30449-6⟩. ⟨hal-03493378⟩
10 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More